---
slug: attia-concierge-care
type: pattern
summary: "A retainer-based clinical relationship running longitudinal preventive medicine for a small panel, with deep diagnostics and selective off-label layering."
created: 2026-05-06
updated: 2026-06-07
evidence_tier: "Practitioner consensus"
cost: "$$$$-$$$$$"
availability: Specialty
regulatory_status: "Standard clinical practice with retainer-based access; off-label prescribing per individual physician judgment"
related:
  longevity-clinic:
    relation: instance-of
    note: "Concierge Longevity Primary Care is the physician-led longitudinal subtype of the broader longevity-clinic category."
  fountain-deep-screen:
    relation: contrasts-with
    note: "Fountain-Life-style annual deep screens center one expensive diagnostic event, while concierge primary care centers longitudinal physician accountability."
  blueprint-bryan-johnson:
    relation: contrasts-with
    note: "Blueprint Protocol is a public n-of-1 self-experiment, while concierge primary care is a regulated retainer-based clinical relationship."
  longevity-medical-tourism:
    relation: contrasts-with
    note: "Concierge primary care is built around a stable home-jurisdiction physician relationship, while medical tourism routes interventions across regulatory regimes."
  longevity-clinic-evaluation:
    relation: tested-by
    note: "Evaluating a Longevity Clinic supplies the credential, evidence, incentive, safety, and exit-path questions a prospective concierge patient should ask."
  apob-screening:
    relation: uses
    note: "ApoB Screening is a routine input the concierge model uses to refine cardiovascular risk beyond standard lipid panels."
  comprehensive-annual-bloodwork:
    relation: uses
    note: "Comprehensive Annual Bloodwork is the diagnostic baseline most concierge longevity practices build their longitudinal plan on."
  vo2max:
    relation: uses
    note: "VO₂max is a core fitness biomarker the concierge model typically programs against."
  biomarker-treadmill:
    relation: violated-by
    note: "Biomarker Treadmill is the failure mode when concierge testing produces action pressure without decision rules."
  stack-creep:
    relation: violated-by
    note: "Stack Creep is the failure mode when retainer-fee access lowers the threshold for adding interventions faster than they can be evaluated."
---

# Concierge Longevity Primary Care (Attia / Early Medical Pattern)

> **Pattern**
>
> A named solution to a recurring problem.

*Concierge longevity primary care is a retainer-based clinical relationship in which one physician or a small team runs longitudinal preventive medicine for a small panel, with deep diagnostics, biomarker-driven planning, and selective clinical-pharmacology layering, in exchange for an annual fee outside ordinary insurance billing.*

*Also known as: longevity concierge medicine, retainer-based longevity practice, preventive-medicine concierge, Attia-model practice, early-medicine practice*

Peter Attia's public "Medicine 3.0" frame makes this model unusually visible, but the model is not a credential and not a proprietary protocol. It is a purchase of physician time, continuity, and preventive-medicine coordination. The medical question is whether that access is governed by evidence, refusal rules, records portability, and ordinary professional accountability.

## Context

Ordinary primary care has structural limits the audience for this category has usually encountered firsthand. A typical fifteen-minute visit doesn't review apoB, Lp(a), VO₂max, body composition, sleep quality, or family-history signals at the level a preventive-medicine clinician would. Specialist referrals take weeks. Records don't follow the patient across systems. The clinician changes every few years.

Concierge primary care addresses that capacity problem by inverting the panel size. A retainer-based physician carries a much smaller panel than ordinary primary care, gets paid through an annual membership rather than per-visit billing, and runs each patient longitudinally: multi-hour intake, deep bloodwork, biomarker-driven planning, and ongoing access. The longevity flavor adds three layers: heavier preventive testing (apoB, Lp(a), CAC or CCTA in selected risk groups, body composition, VO₂max), structured lifestyle prescription (training, sleep, nutrition, alcohol, body composition), and clinician-judged off-label pharmacology when the clinical case supports it.

The category sits between [The Longevity Clinic](longevity-clinic.md) and [Evaluating a Longevity Clinic](longevity-clinic-evaluation.md) as a *subtype*: physician-led, longitudinal, low-panel, retainer-financed. It contrasts with [Fountain-Life-Style Annual Deep Screen](fountain-deep-screen.md), which centers one expensive diagnostic event per year rather than a continuous physician relationship, and with [Blueprint Protocol (Bryan Johnson)](blueprint-bryan-johnson.md), which is a self-published n-of-1 stack rather than a clinic.

Peter Attia's Early Medical practice is the most visible public example of the model and has shaped audience expectations of what concierge longevity care looks like in 2026. Early Medical now describes the practice as accepting new patients, with each new patient assigned a dedicated physician based on profile and assessment. Comparable practices exist in major US metros, in the UK and EU under different financing rules, and in Australia. The model is not a credential; it is a financing-and-panel-design choice layered on top of ordinary internal-medicine or preventive-medicine training.

## Problem

The buyer can mistake access for medicine. A high retainer fee buys time, continuity, and attention. It does not automatically buy better clinical judgment, stronger evidence, or interventions that ordinary preventive medicine refuses on principle. The reader needs to separate what the retainer is paying for from what the medicine is paying for.

There are three failure modes the model is structurally prone to. The first is *intervention drift*: a retainer-fee patient who pays for access exerts continuous pressure to do more, and a physician with a small panel has more time to say yes than a physician with a full waiting room. The second is *testing inflation*: the same retainer covers more frequent and broader testing, which generates incidental findings, follow-up imaging, anxiety, and follow-up cascades that ordinary medicine would have moderated. The third is *evidence asymmetry*: components vary in their proof base, but the patient pays one fee for the whole program and may not see the difference between a guideline-grade lipid plan and a weakly-evidenced supplement protocol.

The strong version of the model resists each failure mode actively. The weak version converts the retainer fee into more of everything.

## Forces

- Continuity and attention have real medical value, but they are not the same as evidence for any specific intervention.
- A small panel lets a clinician do more for each patient, including more of things that don't have strong outcome evidence.
- Off-label prescribing can be ordinary clinical judgment, but it can also drift into commercial pressure when the patient is paying for results.
- The retainer model shifts the clinician's incentive from volume to retention, which can favor patient satisfaction over clinical restraint.
- Insurance fragmentation creates real preventive-care gaps that the concierge model legitimately closes.
- Records portability and outside-specialist coordination depend on the clinic's design, not on the fee level.

## Solution

**Buy the longitudinal physician relationship, not the brand.** The useful version of this model is one named clinician taking medical responsibility for a small panel longitudinally, with explicit decision rules for testing, treatment, and referral, and explicit refusal rules for interventions that don't meet the rules.

The diligence questions are simpler than the marketing makes them look:

| Question | What a strong answer sounds like |
|---|---|
| Who is the treating clinician? | A named, board-certified physician, typically in internal medicine, family medicine, cardiology, or endocrinology, with a stated panel-size cap. |
| What is the panel size? | A specific number, typically 50–300. "We keep panels small" is not a number. |
| Which interventions are inside the retainer, and which are not? | A written scope, including which testing is included, which prescriptions are written by the practice, and which generate separate bills. |
| What is the decision rule for adding a medication? | An explicit threshold or guideline reference, not "we tailor to each patient." Tailoring is a description of practice, not a decision rule. |
| What is the policy on off-label prescribing? | A clear statement of which off-label uses the practice supports, on what evidence, with what monitoring and stopping rules. |
| What happens if I want a second opinion? | A practice that hands over records and welcomes outside review without friction. |
| What happens if I leave? | A clear records-transfer policy, no exit penalty, no proprietary-dashboard hostage situation. |
| How are findings handed off to specialists? | A working referral network with named specialists, not just "we'll find someone." |
| What conflicts of interest exist? | Disclosed financial relationships with supplement lines, device vendors, regenerative-medicine operators, or pharmacy services. |

A strong practice will answer most of these in writing during intake. A weak one will offer aspirational prose ("personalized," "precision," "comprehensive") instead.

The model is most defensible when the clinical content is conservative and the access content is generous. A practice that uses its small panel to do ordinary preventive medicine well (apoB-driven lipid management, blood-pressure control, resistance training and aerobic capacity programming, sleep evaluation, alcohol counseling, GLP-1 agonists for clear cardiometabolic indications, age-and-risk-appropriate cancer screening with sensible decision rules) is doing something the fragmented system rarely does. A practice that uses the same retainer to layer weakly-evidenced supplements, frontier interventions, and biological-age dashboards on top is selling a different proposition.

> **⚠️ Hype Check**
>
> A retainer fee buys time and access. It does not buy clinical evidence for any specific intervention the practice happens to offer. Evidence still has to be evaluated component by component.

## Evidence

**Evidence tier: Practitioner consensus.** No randomized trial has tested "concierge longevity primary care" as a discrete intervention against ordinary primary care. The evidence is component-dependent and structural: retainer-care ethics, off-label prescribing rules, preventive-medicine guidelines for the underlying components, and the consistent observation that adequate clinician time and panel size correlate with better preventive-care delivery.

The ethical and structural frame is well-defined. The AMA's Code of Medical Ethics Opinion 11.2.5 on retainer practices specifies that physicians offering retainer arrangements must present terms clearly, must not imply that the fee buys better medical services than colleagues provide, must support voluntary participation, must help transfer care for patients who opt out, and must base recommendations on evidence, guidelines, judgment, and stewardship. Medicare describes concierge care as a membership-fee arrangement (also called retainer-based or boutique medicine) and notes that the membership fee itself is not covered. Those rules don't endorse the model as longevity care; they govern its conduct as a financing arrangement.

The preventive-medicine evidence base is component-specific. The 2026 ACC/AHA multisociety dyslipidemia guideline replaced the 2018 cholesterol guideline and expanded risk assessment around PREVENT-ASCVD equations, Lp(a), apoB, and coronary artery calcium scoring. A concierge practice that runs that program is delivering current guideline care, not a proprietary longevity protocol. The longevity flavor is the consistency with which the components are applied, not the components themselves.

Off-label prescribing supplies one of the model's most-discussed surfaces. FDA states that once a drug is approved, clinicians may prescribe it for an unapproved use when they judge that use medically appropriate, while noting that FDA has not determined safety and effectiveness for the unapproved use. Off-label use is legal, common, and routine in clinical practice. It is not the same as an FDA-validated longevity claim. Rapamycin and metformin are the two most-cited off-label longevity examples in this category. Rapamycin has no human RCT showing healthspan extension; the PEARL trial (2023) showed safety and some functional improvements in healthy older adults over 48 weeks but didn't establish a longevity endpoint. Metformin has the long-awaited TAME trial framework but no published RCT result showing all-cause healthspan extension in non-diabetic adults. A concierge practice may reasonably prescribe either, with monitoring, but should describe the evidence honestly rather than as proven.

GLP-1 receptor agonists are the most consequential 2026-era addition. SELECT (2023) showed that semaglutide reduced major adverse cardiovascular events by 20% in adults with established cardiovascular disease and overweight or obesity. SURMOUNT-1 (2022) demonstrated mean weight loss of about 21% with tirzepatide. STEP-HFpEF (2023) showed symptomatic and functional benefit in heart failure with preserved ejection fraction. These are guideline-grade results in their indicated populations. A concierge practice that uses them appropriately is delivering current evidence-based cardiometabolic care; one that prescribes them off-label to lean adults for "metabolic optimization" is doing something different and weaker.

The structural evidence on small-panel preventive care is suggestive but indirect. Direct-primary-care and concierge models report longer visits, stronger continuity, and lower utilization in some panel-comparison studies, but those studies are hard to separate from patient selection, income, baseline health, and practice design. None is randomized evidence that concierge care extends life. The more defensible claim is narrower: the financing model removes one bottleneck preventive medicine repeatedly runs into.

The 2026 update doesn't change the structural picture. Cardiovascular risk management got more structured; GLP-1 evidence expanded in cardiometabolic indications; off-label longevity pharmacology gained practitioner attention but not RCT validation for healthy-longevity outcomes. The concierge model's defensibility still rests on longitudinal physician accountability applied to current evidence, not a proprietary edge over ordinary medicine.

## How It Plays Out

A 52-year-old executive with a family history of premature cardiovascular disease, a borderline lipid panel, and no stable primary-care relationship joins a concierge practice. The first six months produce a measured apoB, an Lp(a) baseline, a CAC scan that returns a non-zero score, a structured statin trial calibrated to apoB targets, a blood-pressure plan with home monitoring, a VO₂max baseline, a resistance-training prescription, and a sleep evaluation that catches mild apnea the patient hadn't tested for. None of that is longevity-clinic-exclusive medicine. All of it is current preventive-medicine practice applied consistently. The retainer is buying the consistency.

A 47-year-old joins the same practice and asks about rapamycin, metformin, NAD+, peptides, and a senolytic stack she read about. A strong practice walks each item through evidence tier, candidate criteria, monitoring, and stopping rule, then declines the ones whose case doesn't hold. A weak practice adds most of them, calls the additions "personalization," and bills separately for compounded products through a pharmacy relationship. Same fee, different medicine.

A 61-year-old patient with prediabetes, BMI 31, and elevated apoB receives a guideline-grade GLP-1 prescription, dietary support, resistance-training programming, and a structured statin plan. Over eighteen months, body composition shifts, apoB falls, fasting glucose normalizes, and resting blood pressure improves. The concierge model's value here is straightforward: the patient got coordinated cardiometabolic care a fragmented system was unlikely to assemble.

A 58-year-old joins for the access and ends up over-tested. Repeat full-body MRIs find incidental nodules, repeat blood panels surface borderline values that don't change management, biological-age reports oscillate within their measurement noise, and the patient experiences continuous low-grade clinical anxiety. The retainer didn't cause this; the practice's lack of refusal rules did. The same model with stronger restraint produces the opposite outcome.

A 64-year-old patient leaves the practice after three years. The handoff produces complete records, lab values, imaging reports, clinician interpretation, a written care summary, and a referral letter the next physician can use. The model is doing its job because it has an exit path. A practice without an exit path was never the medical relationship it advertised.

## Consequences

**Benefits.** A well-run concierge longevity practice closes the most reliable preventive-medicine gap in fragmented ordinary care: adequate clinician time applied longitudinally to current evidence. For a patient with complex risk, time scarcity, poor access to coordinated specialists, or a history of fragmented care, that closure has real value. The model also makes clinical accountability legible: one named physician owning the plan, one practice retaining the records, one decision-rule framework applied across testing and treatment.

The model is also one of the few longevity-medicine settings where the right kind of skepticism is rewarded. A patient willing to ask the diligence questions above can find practices that earn the fee through restraint. The best practices in this category resemble high-quality preventive cardiology more than they resemble wellness medicine.

**Liabilities.** The structural failure modes are real. Intervention drift turns continuous attention into continuous additions. Testing inflation generates incidental findings the system then has to manage. Evidence asymmetry collapses guideline-grade care and weakly-evidenced layering into a single experience the patient pays one fee for. The fee itself raises the bar: a five-figure annual cost has to justify itself against the alternative of buying ordinary preventive care directly through a competent internist and using the difference to fund training, sleep, food quality, and time off.

The model can also produce its own antipattern surface. [Biomarker Treadmill](biomarker-treadmill.md) is the natural risk when frequent testing combines with retainer-fee access. [Stack Creep](stack-creep.md) is the natural risk when the retainer lowers the threshold for adding interventions faster than they can be evaluated. The strongest sign that a practice is resisting both is its willingness to subtract: to deprescribe, to stop testing, to decline an intervention the patient is paying to receive.

The practical consequence is a purchase rule the rest of this section already implies: buy clinical accountability and current evidence applied consistently, not the brand or the device list. A practice that can name its decision rules, refusal rules, exit path, and conflicts has built a medical relationship. A practice that can't has built a service relationship with medical decor.

## Sources

- Early Medical. ["Early | Peter Attia's Digital Longevity Program."](https://earlymedical.com/) Accessed June 7, 2026. Primary source for the current public description of Early Medical and the statement that Peter Attia founded it.
- Peter Attia, MD. ["Welcome."](https://peterattiamd.com/start-here/) Accessed June 7, 2026. Primary source for Attia's public description of Medicine 3.0, Early Medical, and his practice's focus areas.
- American Medical Association. ["Retainer Practices."](https://code-medical-ethics.ama-assn.org/ethics-opinions/retainer-practices) *AMA Code of Medical Ethics* Opinion 11.2.5. The retainer-care ethical frame this entry's diligence questions are calibrated against.
- Medicare.gov. ["Concierge Care."](https://www.medicare.gov/coverage/concierge-care) Defines the membership-fee arrangement and its coverage boundary.
- FDA. ["Understanding Unapproved Use of Approved Drugs 'Off Label.'"](https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/understanding-unapproved-use-approved-drugs-label) The off-label prescribing rule that governs much of the model's pharmacology surface.
- American College of Cardiology and American Heart Association. ["ACC, AHA Release New Clinical Guideline For Managing Dyslipidemia."](https://www.acc.org/latest-in-cardiology/journal-scans/2026/03/13/15/20/acc-aha-release-new-clinical-guideline-for-managing-dyslipidemia) March 13, 2026. The 2026 dyslipidemia guideline that defines current preventive cardiology and structures the model's lipid-management surface.
- The Participatory Evaluation of Aging with Rapamycin for Longevity (PEARL) trial. Reported 2023 in healthy older adults, the trial found rapamycin tolerable over 48 weeks with limited functional-endpoint signal and no established longevity endpoint; cited here as illustrative of where off-label rapamycin evidence stands.
- Lincoff, A. Michael, Kathryn Brown-Frandsen, Helen M. Colhoun, et al. ["Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes."](https://www.nejm.org/doi/full/10.1056/NEJMoa2307563) *New England Journal of Medicine* 389 (2023): 2221-2232. The SELECT trial result that anchors current GLP-1 cardiometabolic prescribing.
- Federal Trade Commission. [*Health Products Compliance Guidance*.](https://www.ftc.gov/business-guidance/resources/health-products-compliance-guidance) December 2022. The claim-substantiation rule the model's marketing has to satisfy.
- Direct Primary Care Coalition. ["DPC Mapper and Resource Center."](https://www.dpcare.org/) Reference for direct-primary-care and retainer-based panel-size and structural-care evidence cited above.

## Medical and Legal Boundary

This entry is a reference, not medical advice. It describes published evidence, regulatory status, and common clinical practice patterns. It does not diagnose, prescribe, or replace a clinician's judgment for a specific person.

Concierge longevity primary care can include prescription drugs, off-label pharmacology, hormones, peptides, advanced imaging, and other interventions whose suitability, contraindications, dose, monitoring, adverse-event handling, and follow-up belong to qualified clinicians who can evaluate the individual patient and jurisdiction. Membership in such a practice does not substitute for the patient's responsibility to ask the diligence questions named above and to verify that each component of care has the evidence and monitoring it claims to have.

---

- [Next: Evaluating a Longevity Clinic](longevity-clinic-evaluation.md)
- [Previous: Blueprint Protocol (Bryan Johnson)](blueprint-bryan-johnson.md)